Efficacy of Anlotinib in Advanced Soft Tissue Sarcoma by Prior Lines of Therapy, Age and Dose Modification

Y. Yao,Y. Chi,Z. Fang,S. Wang,G. Huang,Q. Cai,G. Shang,G. Wang,G. Qu,Q. Wu,Y. Jiang,J. Song,J. Chen,X. Zhu,Z. Cai,C. Bai,Y. Lu,Z. Yu,J. Shen,J. Cai

DOI: https://doi.org/10.1093/annonc/mdy299.028

IF: 51.769

2018-01-01

Annals of Oncology

Abstract:Background: ALTER0203 was a randomized phase IIB trial (NCT02449343) that demonstrated single-agent activity of anlotinib in advanced STS (aSTS). The primary endpoint progression-free survival (PFS) was met and presented as an oral presentation in 2018 ASCO. We evaluated the relationship between age, prior lines of therapy, and dose reductions on the efficacy of anlotinib in aSTS. Methods: Median PFS (mPFS) was evaluated in subgroups of prior lines of therapy (0 or 1 prior line; 2+ prior lines), age (< 65 y; ≥65 y), and dose reductions (no dose reduction; ≥1 dose reduction). All analyses were descriptive and exploratory and required cautious interpretation. Results: A total of 158 patients received anlotinib in the ALTER0203 study. Before enrollment, 20 patients of alveolar soft part sarcoma and clear cell sarcoma had no prior line of chemotherapy, 84 patients had received 1 prior line of chemotherapy and 54 patients had received 2+ prior lines of chemotherapy. Median PFS was similar in patients receiving anlotinib who had only 0 or 1 prior line of therapy vs 2+ prior lines of therapy (mPFS, 6.7 vs 6.33 months). In patients receiving anlotinib, mPFS was similar in ages < 65 than ≥65 y (6.33 and 5.9 months, respectively). In patients receiving anlotinib, mPFS was longer in patients requiring ≥ 1 dose reduction vs no reduction (10.43 and 5.73 months, respectively).Table: 1630PSubgroupsNAnlotinib, mPFS, months (95% CI)Lines of therapy0 or 1 prior line1046.7 (4.07-9.33)2+ prior lines546.33 (3.90-8.76)Age< 65 y1526.33 (5.06-7.60)≥65 y65.9 (0.00-14.86)Dose reductionNo dose reduction1445.73 (3.76-7.7)≥ 1 dose reduction1410.43 (-)mPFS, median progression-free survival; CI, confidence interval. Open table in a new tab mPFS, median progression-free survival; CI, confidence interval. Conclusions: In patients receiving anlotinib, longer mPFS was observed in patients requiring ≥ 1 dose reduction. Additionally, mPFS with anlotinib was maintained regardless of lines of therapy or patient age. Clinical trial identification: NCT02449343. Legal entity responsible for the study: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Funding: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Disclosure: All authors have declared no conflicts of interest.